Skip to content

The Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric Varices

Post-balloon Occluded Retrograde Transvenous Obliteration Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric Varices

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03171805
Enrollment
74
Registered
2017-05-31
Start date
2017-06-01
Completion date
2022-12-30
Last updated
2021-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Varix, Liver Cirrhoses, Portal Hypertension

Brief summary

Balloon-occluded retrograde transvenous obliteration (BRTO) has been effective method to manage gastric varices. However, more than one third of patients after BRTO treatment experienced worsening of esophageal varices. The present study was designed to evaluate the effect of post-BRTO propranolol adminstration on the change of esophageal varices.

Interventions

DRUGPropranolol

Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of liver cirrhosis 2. Clinical diagnosis of isolated gastric varices 3. The presenec of spontaneous portosystemic shunt

Exclusion criteria

1. Contradictions to Propranolol 2. Balloon occluded retrograde transvenous obliteration was failed

Design outcomes

Primary

MeasureTime frameDescription
Worsening of esophageal varices rate3 yearsAnalysis

Secondary

MeasureTime frameDescription
Variceal rebleeding rate3 yearsAnalysis
Mortality rate3 yearsAnalysis
Worsening of ascites rate3 yearsAnalysis

Countries

China

Contacts

Primary Contactxuefeng luo
luo_xuefeng@yeah.net02885422311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026